Compare iShares Russell 2000 ETF (IWM) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Russell 2000 ETF vs Mesoblast Limited — how do they compare? iShares Russell 2000 ETF trades at $302.62, while Mesoblast Limited trades at $16.74 (market cap $2.21B). The key difference: iShares Russell 2000 ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| IWM | MESO | |
|---|---|---|
52-Week High | $301.69 | $20.96 |
52-Week Low | $225.45 | $12.88 |
Market Cap | — | $2.21B |
Sector | — | Technology |
Enterprise Value | — | $2.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IWM (iShares Russell 2000 ETF) trades at $302.71, up 0.91% with a bullish technical signal from moving averages. The ETF, tracking 2,000 US small-cap stocks, shows strong institutional interest despite lacking traditional valuation ratios. Recent news highlights small-cap outperformance versus large caps, with institutional investors favoring IWM for its liquidity and options ecosystem. Technical indicators show RSI at 75 suggesting overbought conditions while ADX indicates a strong trend.
Outlook remains positive as small caps benefit from economic conditions, though high RSI suggests near-term consolidation risk. The ETF's broad small-cap exposure offers diversification but faces volatility from economic sensitivity. Institutional accumulation supports medium-term upside potential despite premium valuation concerns versus alternatives.
MESO trades at $16.82, up 0.84% with bullish technical signals from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144.33% net income margin. Recent developments include positive Phase 3 trial progress and BLA filing for heart failure treatment, supported by analyst consensus leaning bullish with 45% buy ratings.
MESO presents a high-risk, high-reward opportunity with promising commercial traction offset by significant losses. Investment thesis hinges on successful pipeline development and profitability turnaround, while risks include clinical trial outcomes, regulatory approvals, and sustained cash burn requiring careful monitoring of execution milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
